Drugs / Trivalent influenza vaccine(BY)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06049927 Comparator | Sep 2023 → May 2024 | influenza | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 3 | NCT05245552 Comparator | Aug 2022 → Aug 2023 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent influenza vaccine(BY) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245552 ↗ |
| Modality | Vaccine | “trivalent influenza vaccine” NCT05245552 ↗ |
| Route | Intramuscular | “The routine of administration is Intramuscular injection into deltoid region.” NCT05245552 ↗ |